MNOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, MediciNova's PE Ratio without NRI is 0.00. MediciNova's 5-Year EBITDA growth rate is 10.40%. Therefore, MediciNova's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for MediciNova's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for MediciNova's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediciNova Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
MediciNova Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, MediciNova's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, MediciNova's PEG Ratio distribution charts can be found below:
* The bar in red indicates where MediciNova's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
MediciNova's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 10.40 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
MediciNova (NAS:MNOV) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of MediciNova's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
Hideki Nagao | director | 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122 |
Jason J Kruger | officer: Chief Financial Officer | 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
Douglas Paulin | officer: Chief Financial Officer | 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
Gaeta Federico C.a. | officer: Chief Scientific Officer | 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
3d Investment Partners Pte. Ltd. | 10 percent owner | 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101 |
3d Opportunity Master Fund | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Carolyn Beaver | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Stepanow Edward C Jr. | officer: Chief Financial Officer | 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037 |
Kazuko Matsuda | officer: Chief Medical Officer | C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
Yuichi Iwaki | director | C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
Carla Reyes | officer: Chief Financial Officer | 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
Yoshio Ishizaka | director | 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
Yutaka Kobayashi | director | 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
Geoffrey Obrien | officer: Vice President | 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
From GuruFocus
By Marketwired • 09-27-2023
By PurpleRose PurpleRose • 07-26-2022
By Stock market mentor Stock market mentor • 01-11-2023
By sperokesalga sperokesalga • 04-30-2023
By GlobeNewswire • 08-18-2023
By Marketwired • 08-16-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 02-08-2023
By GlobeNewswire GlobeNewswire • 01-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.